ATUM Receives Majority Investment from Frazier

ATUM majority investment from Frazier


Summary

ATUM (the “Company”) has received a majority investment from Frazier Healthcare Partners (“Frazier”). The transaction was completed in partnership with co-investors, including Frazier Life Sciences, and the Company’s existing founders and management team. Financial terms of the transaction were not disclosed.

Baird served as exclusive financial advisor to ATUM on this transaction.

About
ATUM accelerates the transition of next-generation biotherapeutics from concept to clinic. By integrating machine learning algorithms, advanced gene synthesis and high-performance cell line development, ATUM overcomes difficult expression and manufacturing hurdles for biopharma innovators worldwide. The Company delivers end-to-end bioengineering solutions that de-risk and shorten drug development timelines. ATUM is headquartered in Newark, California.

Founded in 1991, Frazier is a private equity firm focused exclusively on the healthcare industry. Since its inception, Frazier has raised over $11 billion of capital for private funds and co-investment opportunities and has invested in more than 200 companies over the past 35 years. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier has an office in New York City and invests broadly across the U.S., Canada and Europe. Frazier is headquartered in Seattle, Washington.

CONTACT US TO LEARN MORE

ATUM majority investment from Frazier

Date
November 2026
Company
ATUM
Transaction
M&A - Sellside
Sectors
Healthcare
Verticals
Pharmaceutical Services
Life Sciences Tools & Diagnostics
Target Geography
North America
Acquiror Geography
North America

Share